Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Part1: TUL321

Phase 1

ZZhuhai United Laboratories Co., Ltd.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

PNHRecruiting

PNHPhase 1

Recruiting

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

PNH

NCT07760467

Clinical

Trials by Indication[1]

PNH1 trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Characteristics of Single and Multiple Doses of TUL321 Capsule in Healthy Participants, and the Effect of Food on Pharmacokinetics

Recruiting·ZZhuhai United Laboratories Co., Ltd.·Phase 1·NCT07760467·94 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Part1: TUL321. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Part1: TUL321. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Zhuhai United Laboratories Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: ZZhuhai United Laboratories Co., Ltd.

Related News